Findings from a study of Vicor's PD2i VS to be presented at the Resuscitation Science Symposium 2009

David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Andriy Batchinsky, MD, a researcher with the U.S. Army Institute of Surgical Research (USAISR), will present findings from a study of Vicor's PD2i VS™ (Vital Sign) at the American Heart Association's Resuscitation Science Symposium 2009 on November 14-15, 2009 in Orlando, Florida. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients at risk of sudden cardiac death and trauma victims in need of lifesaving intervention.

Dr. Batchinsky will present "Does Heart-Rate Complexity Analysis Work in the Real World? Changes in the Point Correlation Dimension of Heart Rate During Prehospital Lifesaving Interventions" on November 14, 2009 at 9:30am EST. The study is one of several that have been performed under a collaborative research and development agreement (CRADA) between Vicor and the USAISR entered into in January 2008. The collaboration is continuing. The American Heart Association's Resuscitation Science Symposium (ReSS) is an international forum for fundamental, translational, clinical and population scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury.

"We're extremely pleased and honored to have our PD2i VS™ diagnostic presented at the American Heart Association's Resuscitation Science Symposium by Dr. Batchinsky. Dr. Batchinsky has been actively involved in all of the clinical trials of the PD2i VS™ conducted under our collaborative agreement with the USAISR," stated Mr. Fater. "As we steadily advance commercialization of our PD2i® nonlinear algorithm diagnostics, visibility at prestigious conferences such as this enhances our opportunity to explore new strategic relationships and collaborative efforts that may enable us to identify new applications for the PD2i® nonlinear algorithm," he continued. "All of the clinical trials of our PD2i VS™ conducted under our agreement with the Army reveal the PD2i® nonlinear algorithm to be the only diagnostic capable of consistently and accurately determining severity of injury and the probability of survival in critically injured soldiers and civilians utilizing both 'raw' and 'noisy' EKG data. This is consistent with the EKG data that will be collected from trauma victims in actual battlefield conditions to identify those in need of an immediate lifesaving intervention," Mr. Fater concluded.

The objective of "Does Heart-Rate Complexity Analysis Work in the Real World?" was to evaluate the ability of the PD2i VS™ to distinguish trauma patients receiving lifesaving interventions from those who did not based on analysis of ECGs from 325 prehospital trauma patients. The PD2i® nonlinear algorithm value was calculated on both unedited (raw) and on manually verified, noise- and ectopy-free (clean) ECG sections. In conclusion, researchers found that analysis of complex heart rate variability using the PD2i® nonlinear algorithm and software identifies trauma patients with good sensitivity (low percentage of false negatives) and that results are similar using "raw" or "clean" ECGs. Additional studies of automated trauma triage using the PD2i VS™ are planned.